Skip to main content
SpringerLink
Log in

The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer

The Lahey Guidelines

  • Review Article
  • Published:
Disease Management and Health Outcomes

Abstract

Most breast and ovarian cancers occur sporadically, but an estimated 5 to 10% of cases occur in women with hereditary predisposition to these cancers. Two genes, BRCA1 and BRCA2, have been identified, which, when altered, are thought to be responsible for most cases of hereditary breast and ovarian cancer. Testing for mutations in these genes is now available for women who are at risk. At present, only a small percentage of women have been tested, and identification of high risk women is dependent on pedigree analysis and application of empiric models.

In the general population, the level of risk of hereditary cancer ranges from nonexistent to highly likely. A disease management approach requires identification of the level of risk of each individual in the population, and the development of a specific management strategy of screening and consideration of chemoprevention and prophylactic surgery commensurate with risk. Therefore, risk identification takes on an important role in the allocation of health resources.

This article presents an approach to categorising women who are at increased risk of experiencing hereditary breast or ovarian cancer, whether or not testing is accepted or feasible. An evidence-based approach to screening and measures for prevention are outlined according to level of risk. Occasions when genetic testing would appreciably enhance decisions regarding management are noted.

Clinically useful guidelines for risk assessment and management are intended to reduce the incidence of and morbidity associated with hereditary breast and ovarian cancer. Ongoing research with regard to clinical outcomes of carriers of the BRCA1 or BRCA2 mutation will help refine these strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat 1993; 25: 113–8

    Article  PubMed  CAS  Google Scholar 

  2. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Study Consortium. JAMA 1997 Mar 26; 277(12): 997–1003

    Article  PubMed  CAS  Google Scholar 

  3. Hughes KS, Papa MZ, Whitney T, et al. Prophylactic surgery and inherited cancer predisposition. In: Shall GL, editor. Cancer genetics for the clinician. New York: Plenum Publishing Corporation. In press

  4. Smith SA, Easton DF, Evans DG, et al. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992 Oct; 2(2): 128–31

    Article  PubMed  CAS  Google Scholar 

  5. Ries LAG, Kosary CL, Hankey BF, et al., editors. SEER Cancer Statistics Review, 1973–1995. Bethesda (MD): National Cancer Institute, 1998

    Google Scholar 

  6. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993 Apr; 52(4): 678–701

    PubMed  CAS  Google Scholar 

  7. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995 Jan; 56(1): 265–71

    PubMed  CAS  Google Scholar 

  8. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994 Mar 19; 343(8899): 692–5

    Article  PubMed  CAS  Google Scholar 

  9. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995 Oct; 72(4): 805–12

    Article  PubMed  CAS  Google Scholar 

  10. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997 May 15; 336(20): 1401–8

    Article  PubMed  CAS  Google Scholar 

  11. Roche CA, Lucas MR, Hughes KS. Development of a risk assessment clinic. In: Management of women at high risk for breast cancer. Oxford: Blackwell Science, Inc. In press

  12. Lahey Clinic Risk Assessment Clinic Web Site [online]. Available from: URL: http://www.familycancer.org [Accessed 1999 Sep 1]

  13. Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society Guidelines for the early detection of breast cancer: update 1997. California: American Cancer Society, 1997

    Google Scholar 

  14. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998 Sep 16; 90(18): 1371–88

    Article  PubMed  CAS  Google Scholar 

  15. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992 Oct; 80(4): 708–14

    PubMed  CAS  Google Scholar 

  16. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994 Mar; 83(3): 419–24

    PubMed  CAS  Google Scholar 

  17. Foulkes WD, Wong N, Brunet JS, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997 Dec; 3(12 Pt 1): 2465–9

    PubMed  CAS  Google Scholar 

  18. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998 Jan 31; 351(9099): 316–21

    Article  PubMed  CAS  Google Scholar 

  19. Johannsson OT, Ranstam J, Borg A, et al. Survival of BRCA1 breast and ovarian cancer patients: a population-based study form southern Sweden. J Clin Oncol 1998 Feb; 16(2): 397–404

    PubMed  CAS  Google Scholar 

  20. Crook T, Crossland S, Crompton MR, et al. p53 mutations in BACA1-associated familial breast cancer [letter]. Lancet 1997 Aug 30; 350(9078): 638–9

    Article  PubMed  CAS  Google Scholar 

  21. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 1997 May 24; 349(9064): 1505–10

    Article  Google Scholar 

  22. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989 Jan; 4(1): 1–12

    Article  PubMed  CAS  Google Scholar 

  23. Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 1992 Jul; 80(1): 14–8

    PubMed  CAS  Google Scholar 

  24. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994 Jul 15; 121(2): 124–32

    PubMed  CAS  Google Scholar 

  25. van Nagell Jr JR, Higgins RV, Donaldson ES, et al. Trans vaginal sonography as a screening method for ovarian cancer: a report of the first 1,000 cases screened. Cancer 1990 Feb; 65(3): 573–7

    Article  PubMed  Google Scholar 

  26. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998 Jul 11; 352(9122): 98–101

    Article  PubMed  CAS  Google Scholar 

  27. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998 Jul 11; 352(9122): 93–7

    Article  PubMed  CAS  Google Scholar 

  28. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol 1996; 14(1): 103–10

    PubMed  CAS  Google Scholar 

  29. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998 Aug 13; 339(7): 424–8

    Article  PubMed  CAS  Google Scholar 

  30. Stadel BV, Rubin GL, Webster LA, et al. Oral contraceptives and breast cancer in young women. Lancet 1985 Nov 2; II(8462): 970–3

    Article  Google Scholar 

  31. Struewing JP, Watson P, Easton DF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Natl Cancer Inst Monogr 1995; 17: 33–5

    Google Scholar 

  32. Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991 Oct; 14: 451–4

    PubMed  CAS  Google Scholar 

  33. Goodnight Jr JE, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 1984 Jul; 26(3): 198–201

    Article  PubMed  Google Scholar 

  34. Bowers Jr DG, Radlauer CB. Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with silastic prostheses. Plast Reconstr Surg 1969 Dec; 44(6): 541–4

    Article  PubMed  Google Scholar 

  35. Mendez-Fernandez MA, Henly WS, Geis RC, et al. Paget’s disease of the breast after subcutaneous mastectomy and reconstruction with a silicone prosthesis. Plast Reconstr Surg 1980 May; 65(5): 683–5

    Article  PubMed  CAS  Google Scholar 

  36. Eldar S, Meguid MM, Beatty JD. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 1984 Nov; 148(5): 692–3

    Article  PubMed  CAS  Google Scholar 

  37. Jameson MB, Roberts E, Nixon J, et al. Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies. Clin Oncol (R Coll Radiol) 1997; 9(2): 119–21

    Article  CAS  Google Scholar 

  38. Humphrey LJ. Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast: opinion or knowledge? Am J Surg 1983 Mar; 145(3): 311–2

    Article  PubMed  CAS  Google Scholar 

  39. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 1989 Winter; 13(1): 15–21

    Article  PubMed  CAS  Google Scholar 

  40. Woods JE, Meland NB. Conservative management in full-thickness nipple-areolar necrosis after subcutaneous mastectomy. Plast Reconstr Surg 1989 Aug; 84(2): 258–6

    Article  PubMed  CAS  Google Scholar 

  41. Slade CL. Subcutaneous mastectomy: acute complications and long-term follow-up. Plast Reconstr Surg 1984 Jan; 73(1): 84–90

    Article  PubMed  CAS  Google Scholar 

  42. Fredericks S. A 10-year experience with subcutaneous mastectomy. Clin Plast Surg 1975 Jul; 2(3): 347–57

    PubMed  CAS  Google Scholar 

  43. Amaaki T, Yasumura K, Kami T, et al. Prophylactic subcutaneous total glandectomy for mammary cystic disease, with immediate primary breast reconstruction. Ann Plast Surg 1979 Nov; 3(5): 420–4

    Article  PubMed  CAS  Google Scholar 

  44. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999 Jan 14; 340(2): 77–84

    Article  PubMed  CAS  Google Scholar 

  45. Weber AM, Hewett WJ, Gajewski WH, et al. Serous carcinoma of the peritoneum after oophorectomy. Obstet Gynecol 1992 Sep; 80(3 Pt 2): 558–60

    PubMed  CAS  Google Scholar 

  46. Colditz GA, Stampfer MJ, Willett WC, et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990 Nov 28; 264(20): 2648–53

    Article  PubMed  CAS  Google Scholar 

  47. Daly M, Angelos P, Bryant E, et al. NCCN Practice Guidelines: genetics/familial high-risk cancer screening. Oncology 1999 Nov; 13(11A): 161–83

    Google Scholar 

  48. Schrag D, Kuntz KM, Garber JE, et al. Decision analysis —effects of prophylactic mastectomy and oophorectomy on life expenctancy among women with BRCA1 or BRCA 2 mutations. N Engl J Med 1997 May 15; 336(20): 1465–71

    Article  PubMed  CAS  Google Scholar 

  49. Grann VR, Panageas KS, Whang W Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998 Mar; 16_(3): 979–85

    Google Scholar 

  50. Levine A, Hughes KS. Cost-effectiveness of the identification of women at high risk for the development of breast and ovarian cancer. In: Vogel VG, editor. Management of women at high risk for breast cancer. Boston (MA): Blackwell Science, Inc. In press

Download references

Acknowledgements

We would like to thank Nancy Siegel and Jane Boston for their editorial assistance, and Elaine Hiller, M.S., C.G.C. for her critical review of the manuscript.

Author information

Authors and Affiliations

  1. The Risk Assessment Clinic, The Lahey Clinic, 1 Essex Center Drive, Peabody, Massachusetts, 01960, USA

    Kevin S. Hughes M.D. (Director, Chairman and Clinical Assistant Professor) & Constance A. Roche

  2. Department of Plastic and Reconstructive Surgery, Lahey Clinic, Peabody, Massachusetts, USA

    Timothy Whitney

  3. Department of Gynecology, Lahey Clinic, Burlington, Massachusetts, USA

    Robert McLellan

Authors
  1. Kevin S. Hughes M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Constance A. Roche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy Whitney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert McLellan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin S. Hughes M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hughes, K.S., Roche, C.A., Whitney, T. et al. The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer. Dis-Manage-Health-Outcomes 7, 201–215 (2000). https://doi.org/10.2165/00115677-200007040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200007040-00004

Keywords

Search

Navigation